Multifactorial treatment for improvement of renal function and cardiovascular risk: an ATTEMPT for patients with metabolic syndrome and chronic kidney disease

References

• Athyros VG, Karagiannis A, Ganotakis ES, et al.; for the Assessing The Treatment Effect in Metabolic syndrome without Perceptible diabeTes (ATTEMPT) Collaborative Group. Association between the changes in renal function and serum uric acid levels during multifactorial intervention and clinical outcome in patients with metabolic syndrome. A post hoc analysis of the Assessing The Treatment Effect in Metabolic Syndrome Without Perceptible Diabetes (ATTEMPT) study. Curr Med Res Opin 2011; in press. pagination needs to be added when available
   Google Scholar
• Athyros VG, Ganotakis E, Kolovou G, et al.; for the Assessing The Treatment Effect in Metabolic Syndrome Without Perceptible diabeTes (ATTEMPT) Collaborative Group. Assessing The Treatment Effect in Metabolic syndrome without Perceptible diabeTes (ATTEMPT). A prospective-randomized study in middle aged men and women. Curr Vasc Pharmacol 2011; in press
   Google Scholar
• Drüeke TB, Massy ZA. Atherosclerosis in CKD: differences from the general population. Nat Rev Nephrol 2010;6:723-35
   PubMed Web of Science ®Google Scholar
• Rodriguez-Iturbe B, Correa-Rotter R. Cardiovascular risk factors and prevention of cardiovascular disease in patients with chronic renal disease. Expert Opin Pharmacother 2010;11:2687-98
   PubMed Web of Science ®Google Scholar
• McCullough PA, Verrill TA. Cardiorenal interaction: appropriate treatment of cardiovascular risk factors to improve outcomes in chronic kidney disease. Postgrad Med 2010;122:25-34
   PubMed Web of Science ®Google Scholar
• Efstratiadis G, Tziomalos K, Mikhailidis DP, et al. Atherogenesis in renal patients: a model of vascular disease? Curr Vasc Pharmacol 2008;6:93-107
   PubMed Web of Science ®Google Scholar
• Sarnak MJ, Levey AS, Schoolwerth AC, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003;108:2154-69
   PubMed Web of Science ®Google Scholar
• Schiele F. Renal dysfunction and coronary disease: a high-risk combination. J Nephrol 2009;22:39-45
   PubMed Web of Science ®Google Scholar
• Chronic Kidney Disease Prognosis Consortium, Matsushita K, van der Velde M, Astor BC, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 2010;375:2073-81
   Google Scholar
• van der Velde M, Matsushita K, Coresh J, et al. Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts. Kidney Int 2011 Feb 9. [Epub ahead of print]
   Google Scholar
• Clase CM, Gao P, Tobe SW, et al.; ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial) and TRANSCEND (Telmisartan Randomized Assessment Study in Angiotensin-Converting-Enzyme-Inhibitor Intolerant Subjects with Cardiovascular Disease). Estimated glomerular filtration rate and albuminuria as predictors of outcomes in patients with high cardiovascular risk: a cohort study. Ann Intern Med 2011;154:310-18
   Google Scholar
• Mercado N, Brugts JJ, Ix JH, et al. Usefulness of proteinuria as a prognostic marker of mortality and cardiovascular events among patients undergoing percutaneous coronary intervention (data from the Evaluation of Oral Xemilofiban in Controlling Thrombotic Events [EXCITE] trial). Am J Cardiol 2008;102:1151-5
   PubMed Web of Science ®Google Scholar
• Tsagalis G, Akrivos T, Alevizaki M, et al. Renal dysfunction in acute stroke: an independent predictor of long-term all combined vascular events and overall mortality. Nephrol Dial Transplant 2009;24:194-200
   PubMed Web of Science ®Google Scholar
• Vlek AL, van der Graaf Y, Spiering W, et al. SMART study group. Cardiovascular events and all-cause mortality by albuminuria and decreased glomerular filtration rate in patients with vascular disease. J Intern Med 2008;264:351-60
   PubMed Web of Science ®Google Scholar
• Paraskevas KI, Giannoukas AD, Mikhailidis DP. Renal function impairment in peripheral arterial disease: an important parameter that should not be neglected. Ann Vasc Surg 2009;23:690-9
   PubMed Web of Science ®Google Scholar
• Umemura S, Kawamori R, Matsuoka H, et al. Effects of renal dysfunction on cardiovascular events in diabetic patients with hypertension: challenge-DM Study subgroup analysis. Clin Exp Nephrol 2011;15:64-72
   PubMed Web of Science ®Google Scholar
• Targher G, Zoppini G, Chonchol M, et al. Glomerular filtration rate, albuminuria and risk of cardiovascular and all-cause mortality in type 2 diabetic individuals. Nutr Metab Cardiovasc Dis 2011;21:294-301
   PubMed Web of Science ®Google Scholar
• van Lammeren GW, Moll FL, Blankestijn PJ, et al. Decreased kidney function: an unrecognized and often untreated risk factor for secondary cardiovascular events after carotid surgery. Stroke 2011;42:307-12
   PubMed Web of Science ®Google Scholar
• Genest J, McPherson R, Frohlich J, et al. Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult – 2009 recommendations. Can J Cardiol 2009;25:567-79
   PubMed Web of Science ®Google Scholar
• Paraskevas KI, Kotsikoris I, Koupidis SA, et al. Cardiovascular events in chronic dialysis patients: emphasizing the importance of vascular disease prevention. Int Urol Nephrol 2010;42:999-1006
   PubMed Web of Science ®Google Scholar
• Athyros VG, Mitsiou EK, Tziomalos K, et al. Impact of managing atherogenic dyslipidemia on cardiovascular outcome across different stages of diabetic nephropathy. Expert Opin Pharmacother 2010;11:723-30
   PubMed Web of Science ®Google Scholar
• Karagiannis A, Mikhailidis DP, Tziomalos K, et al. Serum uric acid as an independent predictor of early death after acute stroke. Circ J 2007;71:1120-7
   PubMed Web of Science ®Google Scholar
• Fang J, Alderman MH. Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971-1992. National Health and Nutrition Examination Survey. JAMA 2000;283:2404-10
   PubMed Web of Science ®Google Scholar
• Niskanen LK, Laaksonen DE, Nyyssonen K, et al. Uric acid level as a risk factor for cardiovascular and all-cause mortality in middle-aged men: a prospective cohort study. Arch Intern Med 2004;164:1546-51
   PubMed Web of Science ®Google Scholar
• Kim SY, Guevara JP, Kim KM, et al. Hyperuricemia and coronary heart disease: a systematic review and meta-analysis. Arthritis Care Res (Hoboken) 2010;62:170-80
   PubMed Web of Science ®Google Scholar
• Kim SY, Guevara JP, Kim KM, et al. Hyperuricemia and risk of stroke: a systematic review and meta-analysis. Arthritis Rheum 2009;61:885-92
   PubMed Web of Science ®Google Scholar
• Kowalczyk J, Francuz P, Swoboda R, et al. Prognostic significance of hyperuricemia in patients with different types of renal dysfunction and acute myocardial infarction treated with percutaneous coronary intervention. Nephron Clin Pract 2010;116:c114-22
   PubMed Web of Science ®Google Scholar
• Madero M, Sarnak MJ, Wang X, et al. Uric acid and long-term outcomes in CKD. Am J Kidney Dis 2009;53:796-803
   PubMed Web of Science ®Google Scholar
• Kanbay M, Ikizek M, Solak Y, et al. Uric acid and pentraxin-3 levels are independently associated with coronary artery disease risk in patients with stage 2 and 3 kidney disease. Am J Nephrol 2011;33:325-31
   PubMed Web of Science ®Google Scholar
• Suliman ME, Johnson RJ, García-López E, et al. J-shaped mortality relationship for uric acid in CKD. Am J Kidney Dis 2006;48:761-71
   PubMed Web of Science ®Google Scholar
• Sonoda H, Takase H, Dohi Y, et al. Uric Acid levels predict future development of chronic kidney disease. Am J Nephrol 2011;33:352-7
   PubMed Web of Science ®Google Scholar
• Endo M, Kumakura H, Kanai H, et al. Prevalence and risk factors for renal artery stenosis and chronic kidney disease in Japanese patients with peripheral arterial disease. Hypertens Res 2010;33:911-15
   PubMed Web of Science ®Google Scholar
• Kang DH, Nakagawa T. Uric acid and chronic renal disease: possible implication of hyperuricemia on progression of renal disease. Semin Nephrol 2005;25:43-9
   PubMed Web of Science ®Google Scholar
• Chonchol M, Shlipak MG, Katz R, et al. Relationship of uric acid with progression of kidney disease. Am J Kidney Dis 2007;50:239-47
   PubMed Web of Science ®Google Scholar
• Katsiki N, Athyros VG, Karagiannis A, et al. Hyperuricaemia and Non-Alcoholic Fatty Liver Disease (NAFLD): a relationship with implications for vascular risk? Curr Vasc Pharmacol 2011 Mar 10. [Epub ahead of print]
   Google Scholar
• Athyros VG, Karagiannis A, Hatzitolios AI, et al. SAGE-METS collaborative group. Standardized arrangement for a guideline-driven treatment of the metabolic syndrome: the SAGE-METS study. Curr Med Res Opin 2009;25:971-80
   Google Scholar
• Athyros VG, Elisaf M, Papageorgiou AA, et al. GREACE Study Collaborative Group. Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Am J Kidney Dis 2004;43:589-99
   Google Scholar
• Athyros VG, Mikhailidis DP, Liberopoulos EN, et al. Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with coronary heart disease and metabolic syndrome: a subgroup analysis of the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) Study. Nephrol Dial Transplant 2007;22:118-27
   PubMed Web of Science ®Google Scholar
• Sica DA. Pharmacologic issues in treating hypertension in CKD. Adv Chronic Kidney Dis 2011;18:42-7
   PubMed Web of Science ®Google Scholar
• Hoogwerf BJ. Renin-angiotensin system blockade and cardiovascular and renal protection. Am J Cardiol 2010;105(1 Suppl):30-5 A
   Google Scholar
• Balamuthusamy S, Srinivasan L, Verma M, et al. Renin angiotensin system blockade and cardiovascular outcomes in patients with chronic kidney disease and proteinuria: a meta-analysis. Am Heart J 2008;155:791-805
   PubMed Web of Science ®Google Scholar
• Palmer BF. Management of hypertension in patients with chronic kidney disease and diabetes mellitus. Am J Med 2008;121(8 Suppl):S16-22
   PubMed Web of Science ®Google Scholar
• Fujioka K. Benefits of moderate weight loss in patients with type 2 diabetes. Diabetes Obes Metab 2010;12:186-94
   PubMed Web of Science ®Google Scholar
• Horton ES. Effects of lifestyle changes to reduce risks of diabetes and associated cardiovascular risks: results from large scale efficacy trials. Obesity (Silver Spring) 2009;17(Suppl 3):S43-8
   PubMed Web of Science ®Google Scholar
• Teta D. Weight loss in obese patients with chronic kidney disease: who and how? J Ren Care 2010;36(Suppl 1):163-71
   PubMedGoogle Scholar
• Filippatos TD, Derdemezis CS, Gazi IF, et al. Orlistat-associated adverse effects and drug interactions: a critical review. Drug Saf 2008;31:53-65
   PubMed Web of Science ®Google Scholar
• Katsiki N, Hatzitolios AI, Mikhailidis DP. Naltrexone sustained-release (SR) + bupropion SR combination therapy for the treatment of obesity: ‘A new kid on the block’? Ann Med 2011 Jan 24. [Epub ahead of print]
   Google Scholar
• Riddle MC. Glycemic control and cardiovascular mortality. Curr Opin Endocrinol Diabetes Obes 2011;18:104-9
   PubMed Web of Science ®Google Scholar
• Papanas N, Maltezos E. Oral antidiabetic agents: anti-atherosclerotic properties beyond glucose lowering? Curr Pharm Des 2009;15:3179-92
   PubMed Web of Science ®Google Scholar
• Anfossi G, Russo I, Bonomo K, et al. The cardiovascular effects of metformin: further reasons to consider an old drug as a cornerstone in the therapy of type 2 diabetes mellitus. Curr Vasc Pharmacol 2010;8:327-37
   PubMed Web of Science ®Google Scholar
• Rizos CV, Liberopoulos EN, Mikhailidis DP, et al. Pleiotropic effects of thiazolidinediones. Expert Opin Pharmacother 2008;9:1087-108
   PubMed Web of Science ®Google Scholar
• Dormandy JA, Charbonnel B, Eckland DJ, et al. PROactive investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005;366:1279-89
   Google Scholar
• Lincoff AM, Wolski K, Nicholls SJ, et al. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 2007;298:1180-8
   PubMed Web of Science ®Google Scholar
• Baumgartner I, Hirsch AT, Abola MT, et al. REACH Registry investigators. Cardiovascular risk profile and outcome of patients with abdominal aortic aneurysm in out-patients with atherothrombosis: data from the Reduction of Atherothrombosis for Continued Health (REACH) Registry. J Vasc Surg 2008;48:808-14
   Google Scholar
• Katsiki N, Hatzitolios AI, Mikhailidis DP. Passive smoking: the democratic right of non-smokers to survive. Angiology In press
   Google Scholar
• Aboyans V, Thomas D, Lacroix P. The cardiologist and smoking cessation. Curr Opin Cardiol 2010;25:469-77
   PubMed Web of Science ®Google Scholar
• Pipe AL, Papadakis S, Reid RD. The role of smoking cessation in the prevention of coronary artery disease. Curr Atheroscler Rep 2010;12:145-50
   PubMed Web of Science ®Google Scholar
• Stack AG, Murthy BV. Cigarette use and cardiovascular risk in chronic kidney disease: an unappreciated modifiable lifestyle risk factor. Semin Dial 2010;23:298-305
   PubMed Web of Science ®Google Scholar
• Lassus J, Harjola VP. Cystatin C: a step forward in assessing kidney function and cardiovascular risk. Heart Fail Rev 2011 Mar 23. [Epub ahead of print]
   Google Scholar
• Taglieri N, Koenig W, Kaski JC. Cystatin C and cardiovascular risk. Clin Chem 2009;55:1932-43
   PubMed Web of Science ®Google Scholar
• Rifkin DE, Katz R, Chonchol M, et al. Albuminuria, impaired kidney function and cardiovascular outcomes or mortality in the elderly. Nephrol Dial Transplant 2010;25:1560-7
   PubMed Web of Science ®Google Scholar
• Agrawal V, Marinescu V, Agarwal M, et al. Medscape. Cardiovascular implications of proteinuria: an indicator of chronic kidney disease. Nat Rev Cardiol 2009;6:301-11
   PubMed Web of Science ®Google Scholar
• Guh JY. Proteinuria versus albuminuria in chronic kidney disease. Nephrology (Carlton) 2010;15(Suppl 2):53-6
   PubMedGoogle Scholar
• Weir MR. Microalbuminuria and cardiovascular disease. Clin J Am Soc Nephrol 2007;2:581-90
   PubMed Web of Science ®Google Scholar
• Navaneethan SD, Pansini F, Perkovic V, et al. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database Syst Rev 2009: CD007784
   Web of Science ®Google Scholar
• Kalaitzidis RG, Bakris GL. Serum creatinine vs. albuminuria as biomarkers for the estimation of cardiovascular risk. Curr Vasc Pharmacol 2010;8:604-11
   PubMed Web of Science ®Google Scholar
• de Jong PE, Gansevoort RT. Focus on microalbuminuria to improve cardiac and renal protection. Nephron Clin Pract 2009;111:c204-10; discussion c211
   PubMed Web of Science ®Google Scholar
• Glassock RJ. Is the presence of microalbuminuria a relevant marker of kidney disease? Curr Hypertens Rep 2010;12:364-8
   PubMed Web of Science ®Google Scholar
• Bloch MJ, Basile JN. Review of recent literature: Existing kidney disease classification guideline needs to incorporate degree of proteinuria with estimated glomerular filtration rate to more accurately predict cardiovascular and renal risk. J Clin Hypertens (Greenwich) 2010;12:627-30
   PubMed Web of Science ®Google Scholar
• Athyros VG, Tziomalos K, Gossios TD, et al. GREACE Study Collaborative Group. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. Lancet 2010;376:1916-22
   Google Scholar
• Bader T. Liver tests are irrelevant when prescribing statins. Lancet 2010;376(9756):1882-3
   PubMed Web of Science ®Google Scholar
• Athyros VG, Tziomalos K, Daskalopoulos GN, et al. Statin-based treatment for cardiovascular risk and non-alcoholic fatty liver disease. Killing two birds with one stone? Ann Med 2011;43:167-71
   PubMed Web of Science ®Google Scholar
• Filippatos TD, Elisaf MS. Combination drug treatment in patients with non-alcoholic fatty liver disease. World J Hepatol 2010;2:139-42
   PubMedGoogle Scholar
• Athyros VG, Mikhailidis DP, Didangelos TP, et al. Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study. Curr Med Res Opin 2006;22:873-83
   PubMed Web of Science ®Google Scholar
• Targher G, Chonchol M, Zoppini G, et al. Risk of chronic kidney disease in patients with non-alcoholic fatty liver disease: Is there a link? J Hepatol 2011;54:1020-9
   PubMed Web of Science ®Google Scholar
• Catalano D, Trovato GM, Martines GF, et al. Renal function and severity of bright liver. Relationship with insulin resistance, intrarenal resistive index, and glomerular filtration rate. Hepatol Int 2011 Jan 28. [Epub ahead of print]
   Google Scholar